Division of Surgery, Inflammatory Diseases and Transplantation, Department of Transplantation Medicine, Norwegian PSC Research Center and Section of Gastroenterology, Oslo University Hospital Rikshospitalet, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Semin Liver Dis. 2017 Nov;37(4):314-331. doi: 10.1055/s-0037-1608801. Epub 2017 Dec 22.
The close relationship between primary sclerosing cholangitis (PSC) and inflammatory bowel disease has inspired hypothetical models in which gut bacteria or bacterial products are key players in PSC pathogenesis. Several studies using high-throughput sequencing technology to characterize the gut microbiota in PSC have been published over the past years. They all report reduced diversity and significant shifts in the overall composition of the gut microbiota. However, it remains unclear as to whether the observed changes are primary or secondary to PSC development and further studies are needed to assess the biological implications of the findings. In the present article, we review the published data in perspective of similar studies in other diseases. We discuss aspects of methodology and study design that are relevant to interpretation of the data. Furthermore, we propose that interpretation and further assessments of findings are structured into conceptual compartments, and elaborate three such possible concepts relating to immune function (the "immunobiome"), host metabolism (the "endobiome"), and dietary and xenobiotic factors (the "xenobiome") in PSC.
原发性硬化性胆管炎 (PSC) 与炎症性肠病之间的密切关系激发了一些假说模型,这些模型认为肠道细菌或细菌产物是 PSC 发病机制中的关键因素。过去几年来,已经有几项使用高通量测序技术来描述 PSC 肠道微生物组的研究发表。它们都报告了肠道微生物组多样性降低和整体组成的显著变化。然而,目前尚不清楚观察到的变化是 PSC 发展的原发性还是继发性,需要进一步的研究来评估这些发现的生物学意义。在本文中,我们从其他疾病的类似研究的角度来回顾已发表的数据。我们讨论了与数据解释相关的方法学和研究设计方面。此外,我们提出将对研究结果的解释和进一步评估构建成概念性的组合,并详细阐述了 PSC 中与免疫功能(“免疫组学”)、宿主代谢(“内共生组”)和饮食及外源性因素(“外共生组”)相关的三个这样的可能概念。